关键词： 131I-BSA@CuS, 131I-labeled BSA-modified CuS nanoparticles 5-ALA, 5-Aminolevulinic acid ASIR, age-standardized rates of cancer incidence ATC, anaplastic thyroid carcinoma Au@MSNs, photo-triggered Gold nanodots capped mesoporous silica nanoparticles AuNCs@BSA-I, innovative iodinated gold nanoclusters BRAF, V-Raf murine sarcoma viral oncogene homolog B CBDCA, Carboplatin CDFI, color doppler flow imaging ultrasound CLND, central compartmentalized node dissection CPDA-131I NPs, the 131I-radiolabeled cerebroid polydopamine nano-particles CT, Computed Tomography DOT, Diffuse Optical Tomography DTC, differentiated thyroid cancer ECDT, enhanced chemodynamical therapy EGF, epidermal growth factor EGFR, epidermal growth factor receptor ESMO, European Society of Medical Oncology FDA, U.S. Food and Drug Administration FI, fluorescence imaging FNAB, fine-needle aspiration biopsy FNAs, fine needle aspirations FTC, follicular thyroid carcinoma GC, germinal center HAOA, Hyaluronic Acid and Oleic Acid HYP, hypericin ICG, indocyanine green IJV, internal jugular vein IR825@B-PPNs, Polymeric NPs with bevacizumab and IR825 conjugated on the surface L-A PTA, laparoscopic photothermal ablation MDR, multidrug resistance MTC, medullary thyroid carcinoma Multimodal therapy NIR, near-infrared NIR-FI, near-infrared fluorescence imaging NIR-PIT, near-infrared photoimmunotherapy NIRF, near-infrared fluorescence NMRI, Nuclear Magnetic Resonance Imaging OCT, Optical Coherence Tomography OI, optical imaging OS, overall survival Optical imaging Optical imaging-guided surgery PAI, Photoacoustic Imaging PDT, photodynamic therapy PET, Positron Emission Tomography PGs, parathyroid glands PLP, porphyrin-HDL nanoparticle PTA, photothermal reagents PTC, papillary thyroid carcinoma PTT, photothermal therapy Pd-MOF, porphyrin–palladium metal–organic framework Phototherapy RIT, radioactive iodine therapy ROS, reactive oxygen species SEC, Selenocysteine SV, subclavian vein SiRNA, interfering RNA TC, thyroid cancer TD, Thoracic Duct TF, tissue factor Thyroid cancer mETE, microscopic extrathyroidal extension

来  源：   DOI：10.1016/j.mtbio.2022.100441   PDF(Pubmed)

Abstract：
Thyroid cancer, as one of the most common endocrine cancers, has seen a surge in incidence in recent years. This is most likely due to the lack of specificity and accuracy of its traditional diagnostic modalities, leading to the overdiagnosis of thyroid nodules. Although there are several treatment options available, they are limited to surgery and 131I radiation therapy that come with significant side effects and hence cannot meet the treatment needs of anaplastic thyroid carcinoma with very high malignancy. Optical imaging that utilizes optical absorption, refraction and scattering properties, not only observes the structure and function of cells, tissues, organs, or even the whole organism to assist in diagnosis, but can also be used to perform optical therapy to achieve targeted non-invasive and precise treatment of thyroid cancer. These applications of screening, diagnosis, and treatment, lend to optical imaging\'s promising potential within the realm of thyroid cancer surgical navigation. Over the past decade, research on optical imaging in the diagnosis and treatment of thyroid cancer has been growing year by year, but no comprehensive review on this topic has been published. Here, we review key advances in the application of optical imaging in the diagnosis and treatment of thyroid cancer and discuss the challenges and potential for clinical translation of this technology.
摘要：
甲状腺癌,作为最常见的内分泌癌症之一，近年来发病率激增。这很可能是由于其传统诊断方式缺乏特异性和准确性，导致甲状腺结节的过度诊断。虽然有几种治疗选择，它们仅限于手术和131I放射治疗,这些治疗具有显著的副作用,因此不能满足恶性程度非常高的未分化甲状腺癌的治疗需求.利用光吸收的光学成像，折射和散射特性，不仅观察细胞的结构和功能，组织，器官,甚至整个有机体来协助诊断，但也可用于进行光学治疗，以实现甲状腺癌的靶向非侵入性和精确治疗。这些筛选的应用，诊断,和治疗,赋予光学成像在甲状腺癌手术导航领域的潜力。在过去的十年里，光学成像在甲状腺癌诊断和治疗中的研究逐年增长,但是没有发表关于这个主题的全面评论。这里,我们回顾了光学成像在甲状腺癌诊断和治疗中应用的关键进展，并讨论了该技术在临床应用中的挑战和潜力。
公众号